Back to News
Market Impact: 0.25
METiS TechBio, Eli Lilly Sign $1.1 Billion For AI-Designed Drug Delivery Collaboration
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
METiS TechBio (7666.HK) announced a strategic collaboration with Eli Lilly (LLY) to develop next-generation lipid nanoparticle (LNP) delivery of medicines to specific tissues in the body. The article provides no financial terms, development milestones, or expected timing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
LLY0.55
More News
- Obsessed with CoreWeave and the AI trade? You're missing out on some great stocks
- Factbox-Anthropic’s public benefit fund and how it compares with other big philanthropic efforts
- Jim Cramer says this is the 'magic elixir' driving Tuesday's stock market
- Usio at ld micro main event: growth, leverage and new catalysts
- Jim Cramer's top 10 things to watch in the stock market Tuesday
- ‘I don’t care how it’s done’: Trump pressures Ukraine to cut peace deal
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Augmented Intelligence: AllMind, Elevate Human Judgement With an Accessible, Powerful, Data-Driven Financial AI Toolkit
- AI Research Systems for Hedge Funds: A Pilot Design